Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab - Université de Lorraine
Article Dans Une Revue Clinical Gastroenterology and Hepatology Année : 2021

Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab

Résumé

Patients with Crohn's disease (CD) or ulcerative colitis (UC) often receive combination therapy with an immunomodulator and tumor necrosis factor antagonists, especially infliximab. However, the benefits of combination therapy with vedolizumab and ustekinumab are unclear.

Dates et versions

hal-04214950 , version 1 (22-09-2023)

Identifiants

Citer

Anne Hu, Paulo Gustavo Kotze, Alice Burgevin, Willam Tan, Alison Jess, et al.. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Clinical Gastroenterology and Hepatology, 2021, 19 (7), pp.1366-1376.e2. ⟨10.1016/j.cgh.2020.07.012⟩. ⟨hal-04214950⟩
13 Consultations
0 Téléchargements

Altmetric

Partager

More